Clinical Trials on Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance in Canada
Total 29 results
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR)RecruitingNon-Muscle Invasive Bladder CancerCanada
-
University of British ColumbiaWithdrawnBladder Cancer | High-Risk Cancer | Durvalumab | Non-muscle Invasive | TremelimumabCanada
-
Mansoura UniversityRecruitingNon-Muscle Invasive Bladder CancerEgypt
-
PrecirixTerminatedAdvanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care TreatmentUnited States, Canada
-
AstraZenecaActive, not recruitingNon-muscle-invasive Bladder CancerFrance, Spain, Belgium, Canada, Poland, Germany, Japan, Russian Federation, United Kingdom, Austria, Australia, Netherlands
-
Merck Sharp & Dohme LLCRecruitingHigh-risk Non-muscle Invasive Bladder CancerCanada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Norway, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Co... and more
-
Theralase Inc.University Health Network, Toronto; WCCT Global; Medelis Inc.CompletedNon-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCGCanada
-
Merck Sharp & Dohme LLCRecruitingBladder CancerCanada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
-
Sesen Bio, Inc.CompletedBladder CancerUnited States, Canada
-
Theralase® Technologies Inc.University Health Network, Toronto; Pharma eMarketRecruitingNon-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCGUnited States, Canada
-
Astellas Pharma Global Development, Inc.Seagen Inc.RecruitingCarcinoma in Situ | Urinary Bladder Neoplasms | Non-muscle Invasive Bladder Cancer | Carcinoma Transitional Cell | NMIBCUnited States, Canada, France, Spain, United Kingdom, Germany
-
PfizerActive, not recruitingNon-muscle Invasive Bladder CancerChina, United States, Spain, Belgium, Korea, Republic of, Australia, United Kingdom, Japan, France, Germany, Canada, Russian Federation, Poland, Italy
-
Janssen Research & Development, LLCRecruitingBladder CancerUnited States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Czechia, Japan, Netherlands, India, Canada, Mexico, Australia, Portugal
-
Janssen Research & Development, LLCRecruitingUrinary Bladder NeoplasmsUnited States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Netherlands, Portugal, Australia, Russian Federation, Ukraine
-
National Cancer Institute (NCI)WithdrawnUrothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8Canada
-
Bristol-Myers SquibbTerminatedUrinary Bladder NeoplasmsUnited States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerSpain, United States, Canada, France, United Kingdom
-
Merck Sharp & Dohme LLCSeagen Inc.; Astellas Pharma Global Development, Inc.Active, not recruitingUrinary Bladder Cancer, Muscle-invasiveCanada, United States, Australia, Belgium, France, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Thailand, Ukraine, Argentina, Colombia, Denmark, Germany, Ireland, Israel, Japan, Malaysia, Philippines, Sing... and more
-
Ontario Clinical Oncology Group (OCOG)Cancer Care OntarioActive, not recruitingMuscle-invasive Bladder CancerCanada
-
AstraZenecaActive, not recruitingMuscle Invasive Bladder CancerUnited States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Bristol-Myers SquibbNektar TherapeuticsCompletedBladder Cancer | Bladder Tumor | Muscle-Invasive Bladder CancerRussian Federation, China, Germany, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Greece, Israel, Mexico, Netherlands, Poland, Spain, United Kingdom
-
AstraZenecaRecruitingMuscle Invasive Bladder CancerNetherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
-
Hoffmann-La RocheRecruitingMuscle-invasive Bladder CancerBelgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdActive, not recruitingUrinary Bladder Neoplasms | Muscle-Invasive Bladder CancerRussian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerRecurrent Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7United States, Canada
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Breast Carcinoma | Invasive Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | HER2-Positive Breast CarcinomaUnited States, Korea, Republic of, Canada
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Seagen Inc.RecruitingAnatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC... and other conditionsUnited States, Canada, Puerto Rico